Pay in 4 interest-free payments of $6.88 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
Kawabe,B.K
Emergence of immune escape at dominant SARS-CoV-2 killer T cell epitope
Known for its regenerative properties, it helps in tissue repair, reduces inflammation, and supports gut health
Heres the realistic timeline: Phase 3 trials (AMAZE program): - AMAZE 1 (obesity) started February 2026, enrolling ~1,150 participants - Primary completion estimated: June 2029 - Phase 3 in T2D also being planned following the ADA 2026 data US FDA approval (projected): Q4 2030 at the earliest (GlobalData estimate) EU EMA approval (projected): Q1 2031 at the earliest Bulgaria and Eastern Europe: Typically 612 months after EMA approval for market access, depending on national reimbursement negotiations
US$ 28.71
US$ 24.17
US$ 24.73
US$ 24.76
US$ 21.67
US$ 20.43
